iBio Inc Dossier - Source-backed chat

iBio Inc

IBIONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.25

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.18Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $75.9M

Shares Outstanding 64.3M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

iBio, Inc. has successfully transitioned into a clinical-stage biotechnology company following the dosing of its first participant in the Phase 1 clinical trial of IBIO-600 in Australia. The company's strategic pivot toward AI-driven precision antibody therapies for cardiometabolic, obesity, and cardiopulmonary diseases is supported by highly promising preclinical data. Specifically, its lead obesity candidate, IBIO-610, demonstrated a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass in obese non-human primates while preserving lean mass. Backed by a strong cash position of $74.8 million as of March 31, 2026, and an additional $17 million raised from subsequent warrant exercises, iBio has extended its cash runway into the fourth quarter of fiscal year 2028. This robust financial cushion mitigates near-term funding risks, allowing the company to focus on clinical execution and pipeline expansion.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.20

Mean target$5.40

High · most bullish analyst$7.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

The bear case is defined by potential clinical delays or adverse safety signals in the IBIO-600 Phase 1 trial, which would severely damage investor confidence in the platform. Higher-than-expected R&D expenses could accelerate the cash burn rate, shortening the runway and forcing dilutive equity financing. Intense competition in the obesity and cardiometabolic space from larger, well-funded pharmaceutical companies could also marginalize iBio's market prospects, driving the stock down toward its historical lows.

Base CaseCentral scenario

$5.0050%

The base case assumes steady execution of the Phase 1 trial for IBIO-600 with initial safety readouts aligning with expectations. Preclinical development for IBIO-610 remains on track for a first-in-human trial in early 2027. The company maintains disciplined cost management, keeping its cash runway extended into 2028. Under this scenario, iBio's valuation aligns with the consensus analyst target as it achieves key clinical milestones.

Bull CaseUpside scenario

$7.0030%

The bull case is driven by rapid clinical progress of IBIO-600, demonstrating best-in-class potential in preserving lean mass while promoting fat loss in obese adults. Positive Phase 1 safety and tolerability data would validate iBio's AI-driven discovery platform, attracting lucrative pharmaceutical partnerships. Additionally, the successful IND filing and clinical entry of IBIO-610 in early 2027, alongside positive development of its bispecific antibody program for PH-HFpEF, would position iBio as a premier multi-asset cardiometabolic player, driving the stock toward the high-end analyst target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transitioned to a clinical-stage biotech company with the first participant dosed in the IBIO-600 Phase 1 trial.
Strong preclinical data for IBIO-610 showing fat-selective weight loss (6.7% visceral fat reduction) in non-human primates.
Robust cash runway extending into Q4 fiscal year 2028, supported by $74.8 million in cash/debt securities and $17 million in subsequent warrant exercises.
Strategic pipeline expansion into high-unmet-need indications like pulmonary hypertension associated with heart failure (PH-HFpEF).

Key Investment Risks

High operational cash burn rate driven by advancing multiple preclinical and clinical programs simultaneously.
Clinical trial risks, including potential safety issues, slow enrollment, or failure to replicate preclinical efficacy in humans.
Intense competition in the obesity and cardiometabolic therapeutic space from established pharmaceutical giants.
Dependence on regulatory approvals from agencies such as the FDA and Australia's TGA.

Thesis Invalidation Triggers

Failure of IBIO-600 to show acceptable safety or tolerability in its Phase 1 clinical trial.
Significant delay in the IND filing or clinical trial initiation for IBIO-610 beyond early 2027.
Unanticipated acceleration of cash burn that reduces the cash runway to less than 12 months without securing non-dilutive funding.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.